Trial Profile
An Open, Prospective Study to Compare the Safety and Efficacy of Raltegravir vs. Atazanavir / Ritonavir, Both in Combination With Tenofovir DF and Emtricitabine, in the Treatment of HIV-infection in ART Naive Subjects With HCV Co-infection.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 30 Jul 2015
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Atazanavir; Emtricitabine/tenofovir disoproxil fumarate; Ritonavir
- Indications HIV infections
- Focus Adverse reactions
- 02 Jun 2015 Status changed from recruiting to withdrawn prior to enrolment, as reported by ClinicalTrials.gov.
- 27 Oct 2010 New trial record